Medicines for the Brain

We believe the key to treating neurodegenerative disease is to intervene early.

Millions of people worldwide suffer from neurodegenerative diseases that impair memory, focus and thinking and impact their ability to go about their daily lives. By applying our novel approach, we believe the synaptic dysfunction responsible for disease symptoms and progression can be reversed before the death of nerve cells.

Our Approach

A Focus On Neurodegenerative Disease

Dementia with Lewy Bodies

Patients with this disease accumulate protein deposits, called Lewy bodies, in the brain’s nerve cells. This negatively affects cognitive ability, including attention, judgement, and reasoning, along with motor function.

Alzheimer’s Disease

Alzheimer’s disease is a condition characterized by memory loss, disorientation and other cognitive deficits that worsen as the disease progresses.

Stroke Recovery

Stroke, caused by blockage of arteries supplying blood to the brain, is the number one cause of long-term disability in adults. Most stroke survivors have some level of recovery after a stroke. However, in moderately severe and severe stroke the recovery is often incomplete.

HOPE THROUGH SCIENCE

Introducing Neflamapimod

We are developing neflamapimod – an oral, selective small molecule inhibitor of the protein kinase p38 alpha. Extensive research has shown that p38 alpha is a key driver of synaptic dysfunction, the reversible aspect of the neurodegenerative process. The preclinical data with neflamapimod, along with evidence from recent phase 2 clinical studies in dementia with Lewy bodies (DLB) and in Alzheimer’s disease (AD), strongly suggest that inhibition of p38 alpha by neflamapimod reverses the synaptic dysfunction that underlies development of symptoms and disease progression in the early stages of many neurological disorders.

Pipeline

CervoMed’s Approach for Dementia with Lewy Bodies

CervoMed In The News

Podcast: Biotech 2050 - Episode #210

Press Releases